Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have been assigned an average rating of “Moderate Buy” from the eleven brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $28.3344.

BCAX has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. BTIG Research reissued a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Wells Fargo & Company boosted their price target on shares of Bicara Therapeutics from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Citizens Jmp started coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They set a “market perform” rating and a $31.00 price target on the stock. Finally, Wedbush reissued an “outperform” rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a research note on Tuesday, January 13th.

Insider Transactions at Bicara Therapeutics

In other Bicara Therapeutics news, COO Ryan Cohlhepp sold 12,500 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $18.68, for a total transaction of $233,500.00. Following the sale, the chief operating officer directly owned 189,141 shares in the company, valued at $3,533,153.88. This represents a 6.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Ivan Hyep sold 1,882 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $18.15, for a total value of $34,158.30. Following the completion of the sale, the chief financial officer directly owned 145,355 shares of the company’s stock, valued at $2,638,193.25. The trade was a 1.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 18,359 shares of company stock valued at $339,630.

Institutional Trading of Bicara Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC bought a new stake in Bicara Therapeutics in the first quarter worth $248,000. Woodline Partners LP raised its stake in shares of Bicara Therapeutics by 26.5% in the first quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock valued at $4,543,000 after acquiring an additional 72,998 shares during the period. Nan Fung Trinity HK Ltd. bought a new stake in shares of Bicara Therapeutics in the 2nd quarter worth about $3,185,000. Geode Capital Management LLC lifted its holdings in shares of Bicara Therapeutics by 36.8% in the 2nd quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock worth $6,248,000 after acquiring an additional 180,833 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey boosted its stake in shares of Bicara Therapeutics by 119.6% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,109 shares of the company’s stock worth $75,000 after purchasing an additional 4,417 shares during the period.

Bicara Therapeutics Stock Up 5.9%

Shares of Bicara Therapeutics stock opened at $16.40 on Tuesday. Bicara Therapeutics has a twelve month low of $7.80 and a twelve month high of $19.71. The business has a 50-day moving average price of $16.47 and a 200-day moving average price of $15.40. The firm has a market cap of $898.39 million, a price-to-earnings ratio of -7.32 and a beta of -0.79.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.